Captopril

Introduction Overview

Generic Name

captopril

Brand Name

Capoten

Dosage Form

oral tablet (100 mg; 12.5 mg; 25 mg; 50 mg)

Drug Class

Angiotensin Converting Enzyme Inhibitors

Pharmacokinetics

Absorption:
Captopril is absorbed rapidly and incompletely after oral administration, with peak plasma concentrations typically achieved within 1 hour. The drug’s bioavailability ranges from approximately 70% to 90%, although interindividual variability occurs due to first-pass metabolism and the presence of food. Absorption is maximized when captopril is taken on an empty stomach; hence, clinical guidelines recommend administration at least one hour before meals. The absorption rate can be influenced by gastrointestinal motility and pH.

Distribution:
Once absorbed, captopril is distributed widely throughout the body’s tissues. It is approximately 25-30% bound to plasma proteins, primarily albumin. The volume of distribution typically ranges from 0.5 to 1.0 L/kg, reflecting its moderate tissue penetration. Captopril crosses the placental barrier but does not significantly bind to erythrocytes. It is not extensively distributed in the cerebrospinal fluid. The drug’s distribution is clinically significant in the context of its effect on cardiac and renal tissues.

Metabolism:
Captopril undergoes minimal hepatic metabolism. Unlike many ACE inhibitors, it does not require biotransformation into active metabolites for efficacy. This attribute contributes to its relatively rapid onset of action. The major metabolic pathway involves the formation of disulfide dimers and conjugation with cysteine in plasma, forming inactive complexes. Captopril's sulfhydryl group is responsible for its unique properties but also predisposes it to oxidation.

Elimination:
Captopril is primarily eliminated via the kidneys through glomerular filtration and tubular secretion. Approximately 50-75% of an oral dose is excreted unchanged in urine within 24 hours. The elimination half-life is approximately 2 hours; however, with repeated dosing, the half-life may extend slightly due to accumulation in renal impairment. Dose adjustments are necessary in patients with compromised renal function to prevent accumulation and toxicity. Dialysis can effectively remove captopril from circulation. The drug's renal clearance is influenced by urine pH, and alkaline urine may reduce excretion.

Dosage Forms

Available Dosage Forms:
Captopril is commercially available as oral tablets in the following strengths: 12.5 mg, 25 mg, 50 mg, and 100 mg formulations. These tablets are designed for systemic absorption and are recommended to be taken on an empty stomach to enhance bioavailability. No intravenously administered formulations are approved, limiting administration routes to oral use only.

Dosages for Adults and Adolescents:
For hypertension, the usual initial adult dose is 25 mg orally two to three times daily, administered at least one hour before meals for optimal absorption. The maintenance dose typically ranges up to 50 mg three times daily, with a maximum of 450 mg daily given in divided doses if necessary, especially in resistant hypertension. For congestive heart failure, initial dosages commence at 25 mg three times daily, with careful titration to a target maintenance dose of 50 mg three times daily for at least two weeks, adjusting for hemodynamic tolerance.
In patients with left ventricular dysfunction post-myocardial infarction, the regimen begins with an initial 6.25 mg dose, progressing to 12.5 mg three times daily and eventually up to 50 mg three times daily over weeks. Diabetic nephropathy is treated with a consistent 25 mg dose three times daily, with augmentation by additional antihypertensives if needed.

Specific Patient Populations:
In individuals with renal impairment, dosages must be cautiously titrated, often starting at lower doses to account for decreased elimination and to prevent hyperkalemia or hypotension. Patients with hypotension, hyponatremia, or hypovolemia initiating heart failure therapy should start with reduced doses (6.25 to 12.5 mg) to mitigate adverse effects.
Elderly patients may require careful monitoring but generally receive similar dosing regimens with adjustments as clinically indicated. Use in pediatric populations is limited and should be based on specialized guidance.

Mechanism Of Action

Captopril acts as a potent competitive inhibitor of angiotensin-converting enzyme (ACE), a zinc metallopeptidase responsible for the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By inhibiting ACE, captopril decreases the synthesis of angiotensin II, leading to vasodilation and reduced blood pressure. Reduced angiotensin II levels also diminish aldosterone secretion, causing decreased sodium and water retention, which further contributes to lowering of blood volume and blood pressure.

At the molecular level, captopril’s sulfhydryl (-SH) functional group binds tightly to the zinc ion in the active site of ACE, effectively preventing substrate access. This unique chemical moiety differentiates captopril from other ACE inhibitors that typically possess carboxyl or phosphinyl groups. The sulfhydryl group may also lead to antioxidant effects, scavenging free radicals and providing protective vascular benefits.

By inhibiting ACE, captopril increases bradykinin levels, a vasodilatory peptide normally degraded by ACE. Elevated bradykinin contributes to vasodilation through the release of nitric oxide and prostacyclin from endothelial cells. This enhanced bradykinin-mediated effect is linked to some of captopril’s therapeutic benefits as well as its adverse effects such as cough and angioedema.

Clinically, captopril’s inhibition of the renin-angiotensin-aldosterone system (RAAS) not only reduces systemic vascular resistance and blood pressure but also improves cardiac remodeling and function in heart failure and post-myocardial infarction patients. Comparative studies indicate captopril’s rapid onset and short half-life demand multiple daily dosing, differing from longer-acting ACE inhibitors, but its efficacy in reducing morbidity and mortality in cardiovascular disease is well established. Research has demonstrated captopril’s effectiveness in diabetic nephropathy through renal hemodynamic modulation and reduction of proteinuria.

Pharmacological Actions

Competitive inhibition of angiotensin-converting enzyme, reducing angiotensin II levels.
Vasodilation leading to decreased systemic vascular resistance and blood pressure.
Reduction of aldosterone secretion resulting in decreased sodium and water retention.
Increase in bradykinin levels causing enhanced vasodilation and endothelial function.
Antioxidant properties due to sulfhydryl group, potentially protecting against oxidative stress.
Improvement of cardiac remodeling and function in heart failure and post-MI patients.
Reduction of proteinuria and slowing progression of diabetic nephropathy.
Modulation of neurohormonal activation, beneficial in congestive heart failure management.
Decreases preload and afterload, easing myocardial workload.
Potential inhibition of sympathetic nervous system activity as secondary effect.

Therapeutic Or Clinical Uses

Treatment of hypertension to lower elevated blood pressure alone or in combination.
Management of congestive heart failure to improve symptoms and reduce morbidity.
Improvement of survival and reduction of heart failure risk post-myocardial infarction with left ventricular dysfunction.
Treatment of diabetic nephropathy in type 1 diabetic patients with proteinuria and retinopathy.
Reduction of proteinuria and preservation of renal function in diabetic kidney disease.
Management of hypertensive emergencies with cautious dosage titration.
Adjunctive therapy in patients with left ventricular hypertrophy to prevent heart failure progression.
Use in patients requiring renin-angiotensin system blockade for cardiovascular protection.
Therapy in proteinuric kidney diseases beyond diabetic nephropathy.
Part of guideline-directed medical therapy for heart failure with reduced ejection fraction.

Side Or Adverse Effects

Persistent dry cough due to increased bradykinin levels in pulmonary tissue.
Hypotension, especially after initial doses or in volume-depleted patients.
Hyperkalemia resulting from decreased aldosterone secretion.
Rash and mild skin itching due to hypersensitivity reactions.
Dysgeusia or altered sense of taste attributed to sulfhydryl group.
Leukopenia or agranulocytosis presenting as signs of infection or fever.
Angioedema characterized by swelling of face, lips, tongue, and throat, potentially life-threatening.
Renal impairment or acute kidney injury, particularly in bilateral renal artery stenosis.
Elevated liver enzymes and rare instances of hepatotoxicity.
Chest pain, palpitations, or arrhythmias in rare cases.
Fatigue, dizziness, or headache associated with hypotensive effects.
Elevated blood urea nitrogen and serum creatinine during therapy.
Gastrointestinal disturbances such as nausea and vomiting.
Electrolyte imbalances including hyponatremia and hypoglycemia in diabetic patients.
Photosensitivity reactions reported in some individuals.

Precautions

Inform healthcare providers about allergies to captopril or other ACE inhibitors.
Avoid use during pregnancy due to risk of fetal injury or death; discontinue immediately if pregnancy occurs.
Caution in patients with history of angioedema or severe allergic reactions.
Monitor renal function and electrolytes regularly, especially in patients with kidney disease or on diuretics.
Avoid concomitant use with aliskiren in diabetic patients or in those with renal impairment.
Initiate treatment at lower doses in hypotensive, hyponatremic, or hypovolemic patients to reduce risk of adverse effects.
Use cautiously in patients on low-salt diets or receiving medications that affect potassium balance.
Inform patients to report symptoms of infection, unusual bruising, bleeding, or persistent cough.
Avoid potassium supplements and salt substitutes unless specifically advised by a healthcare provider.
Be vigilant in patients with connective tissue diseases such as lupus, rheumatoid arthritis, or Marfan syndrome.
Monitor for dehydration in conditions causing increased fluid loss, such as vomiting, diarrhea, or excessive sweating.
Use cautiously in patients undergoing surgery or during anesthesia to avoid hypotension.
Adjust doses in elderly patients or those with hepatic impairment based on clinical response.
Avoid abrupt discontinuation; taper under medical supervision if necessary.
Educate patients on recognizing signs of angioedema or allergic reactions.

Warnings

Do not use captopril during pregnancy, especially in the second and third trimesters.
Risk of angioedema requiring immediate medical attention.
Potential for severe hypotension with first doses in volume- or salt-depleted patients.
Possibility of acute renal failure in patients with bilateral renal artery stenosis or renal impairment.
Hyperkalemia risk when used with potassium-sparing diuretics, potassium supplements, or salt substitutes.
Increased risk of neutropenia or agranulocytosis, necessitating blood count monitoring.
Do not administer within 36 hours before or after sacubitril-containing medications due to serious angioedema risk.
May cause false results in urine protein testing; laboratory should be informed of captopril use.
Avoid NSAIDs concomitantly in patients at risk of renal impairment or heart failure exacerbation.
Captopril may mask signs of hypoglycemia in diabetic patients treated with insulin or oral hypoglycemics.
Close monitoring required when combined with immunosuppressants or chemotherapy agents.
Discontinue and seek emergency care if severe allergic reactions or anaphylaxis occur.
May exacerbate symptoms of systemic lupus erythematosus or other autoimmune conditions.
Avoid sudden position changes to reduce dizziness and falls due to hypotension.
Use with caution during lactation as captopril passes into breast milk and safety is not well established.

Contraindication

Known hypersensitivity to captopril or any other ACE inhibitor.
History of angioedema related to previous ACE inhibitor therapy.
Pregnancy, due to potential for fetal injury or death.
Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment.
Bilateral renal artery stenosis or single kidney with unilateral renal artery stenosis.
Use within 36 hours of switching to or from sacubitril-containing products.
Patients with a history of hereditary or idiopathic angioedema.
Severe hypotension or shock conditions.
Concomitant use with neprilysin inhibitors without appropriate washout period.
Known hypersensitivity to sulfhydryl-containing compounds if cross-reactivity is suspected.
Severe hepatic impairment with cholestasis and jaundice where use may exacerbate condition.
Use in neonates and infants due to limited safety data and risk of adverse effects.
Hypersensitivity to inactive ingredients in tablet formulations if identified.
Concurrent use with concomitant medications that severely lower blood pressure without medical supervision.
Any condition where ACE inhibition is deemed clinically inappropriate by healthcare provider.

Drug Interactions

Potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride) increase risk of hyperkalemia.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, naproxen may reduce antihypertensive effect and increase risk of renal impairment.
Co-administration with aliskiren is contraindicated in diabetic patients or those with renal impairment.
Immunosuppressants like temsirolimus, sirolimus, and everolimus may potentiate nephrotoxicity.
Other antihypertensive agents may have an additive hypotensive effect.
Diuretics may potentiate first-dose hypotension, necessitating close monitoring when initiating therapy.
Lithium levels may be increased by ACE inhibitors, raising lithium toxicity risk.
Concomitant use with sacubitril-containing drugs within 36 hours increases angioedema risk.
Use with insulin and oral hypoglycemic agents requires careful monitoring for hypoglycemia.
Drugs that alter renal function or electrolyte balance can exacerbate adverse effects.
Combination with gold therapy (e.g., auranofin) may increase risk of nitritoid reactions.
Concurrent usage with systemic corticosteroids or anti-inflammatory agents may affect blood pressure control.
Potential interactions with certain antibiotics and antifungals that affect renal function.
May interfere with some diagnostic laboratory tests, such as urine protein assays.
Herbal supplements like licorice may counteract antihypertensive effects.

Preparations Of The Drug

Captopril oral tablets are available in strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg.
Tablets designed for oral administration with instructions to take on an empty stomach to optimize absorption.
No intravenous forms are available; oral preparations are used exclusively.
Commercial preparations contain inactive excipients such as lactose, microcrystalline cellulose, and magnesium stearate.
Packaged in blister packs or bottles to maintain stability and moisture protection.
Capsule formulations are generally not marketed; the tablet form is standard.
Formulations are FDA-approved for multiple indications including hypertension and heart failure.
Available under the brand name Capoten and generic versions in equivalent dosages.
Storage instructions recommend tightly closed containers at room temperature, protected from moisture and heat.
Patient information leaflets accompany packaging with usage directions and safety information.
No sustained-release or extended-release forms are commonly available, requiring multiple daily dosing.
Standard pharmaceutical manufacturing controls ensure consistent potency and quality.
No known parenteral or topical captopril formulations marketed for clinical use.
Formulations may be combined with diuretics in separate pharmaceutical products but not within a single tablet.
Generic preparations are bioequivalent to brand-name Capoten tablets.